"The
Report Mesenchymal Stem Cells - Advances & Applications provides
information on pricing, market analysis, shares, forecast, and
company profiles for key industry participants. -
MarketResearchReports.biz"
EXECUTIVE SUMMARY
This global strategic report
is produced for:
- Management of stem cell companies
- Management of regenerative therapy companies
- Stem cell industry investors
It is designed to increase
your efficiency and effectiveness in:
- Commercializing mesenchymal stem cell (MSC) products, technologies, and therapies
- Making intelligent investment decisions
- Launching high-demand products
- Selling effectively to your client base
- Increasing revenue from MSC products and services
- Taking market share from your competition
Mesenchymal stem cells (MSCs)
are multipotent stem cells that can differentiate into a variety of
cell types, including osteoblasts, chondrocytes, myocytes,
adipocytes, beta-pancreatic islets cells, and potentially, neuronal
cells. MSCs are of intense therapeutic interest because they
represent a population of cells with the potential to treat a wide
range of acute and degenerative diseases.
MSCs are advantageous over
other stem cells types for a variety of reasons: they avoid the
ethical issues that surround embryonic stem cell research, and
repeated studies have found MSCs to be immuno-privileged, which make
them an advantageous cell type for allogenic transplantation. MSCs
reduce both the risks of rejection and complications of
transplantation. Recently, there have been advances in the use of
autologous mesenchymal stem cells to regenerate human tissues,
including cartilage, meniscus, tendons, bone fractures, and more.
View Report At
:http://www.marketresearchreports.biz/analysis/301052
This global strategic report
explores recent advances in MSC research applications, research
priorities by market segment, and the competitive environment for MSC
research products. It also identifies trend and growth patterns
within the MSC industry. Because it is important for pharmaceutical
companies interested to understand underlying forces affecting the
MSC market, this report also presents a range of topics that apply to
these companies, including how advances in MSC research can reveal
potential new drug targets, improve methods of drug delivery, and
provide personalized treatment strategies.
Literature and data concerning
the biology and differentiation potential of mesenchymal stem cells
(MSCs) has expanded rapidly over the past 10 years, with more than
13,000 publications now exploring aspects of MSC biology, behavior,
and applications. In particular, MSCs appear to be an exceptionally
promising tool for cell therapy because of their unusual
characteristics, which partially mimic those of embryonic stem cells,
while having advantages in terms of availability, expandability,
transplantability, and ethical implications.
Interest in therapeutic
applications of human MSCs arises from their diverse ability to
differentiate into a range of cell types, as well as from their
ability to migrate to sites of tissue injury/inflammation or tumor
growth. These localization properties present a promising strategy
for targeted introduction of therapeutic agents through MSC gene
therapy. In addition, MSCs possess strong immunosuppressive
properties that medical researchers are exploiting for both
autologous as well as heterologous therapies.
Clinical Progress with MSCs
As mentioned, mesenchymal stem
cells (MSCs) have inspired a lot of activity over the past ten years
as a novel therapeutic model for a wide range of diseases. Presently,
MSCs-based clinical trials are being conducted for twelve types of
disease conditions, with many completed trials showing their safety
and efficacy.
The clinical utility of MSCs
are mostly attributed to their four key biological properties, which
are their potential to:
- Migrate to sites of inflammation caused by tissue injury when injected intravenously
- To get differentiated into different cell types
- To release different bioactive molecules having the potential of stimulating recovery of injured cells and preventing inflammation
- To accomplish immunomodulatory functions
Currently, there are 128
clinical trials involving MSCs are in progress in different parts of
the world, including China, the European Union, the United States,
the Middle East, and South Korea. Among these trials, 45 (35%) are
exploiting MSCs for various disease indications. Currently, four
major clinical trials using MSCs have reached Phase III. Stempeutics
Research’s product candidate Stempeucel is being evaluated in two
centers for treating critical leg ischemia. Prochymal is the product
candidate from Osiris Therapeutics and it is being used for treating
graft vs. host disease (GvHD). The company is also testing Prochymal
for treating Crohn’s disease in another Phase III trial. The
Australian company Mesoblast is testing an ‘off-the-shelf’
mesenchymal precursor product candidate for treating patients with
hematological malignancies.
Since 1968, bone marrow
transplantation (BMT) has been the gold standard treatment for blood
cancer patients and others with genetic blood disorders. Each year
more than 60,000 bone marrow transplantations are performed
worldwide, and 58% of these procedures use autologous bone marrow and
42% of the cases use allogeneic bone marrow. Currently, the use of
bone marrow is being replaced by the utilization of MSCs for some
conditions.
The majority of cell therapy
products currently being marketed are meant to address
musculoskeletal conditions, and most of these products use MSCs as a
component.
Download
Sample copy of this Report at:
Report Objectives
The purpose of this report is
to describe the current status of mesenchymal stem cells (MSCs)
research, the ongoing clinical trials involving MSCs, late stage MSCs
clinical trials, and the possible uses of MSCs in cell therapy. As
MSC cell therapy is an integrated component of other cell therapies
and regenerative medicines (RM), the report also gives a brief
overview of the RM industry and overall cell therapy (CT) industry.
Thus, the main objectives
are to consider the following:
- Current status of global regenerative medicine (RM) industry in the utilization of stem cells in general and MSCs in particular.
- Current status of global cell therapy (CT) industry, the application of cell therapy in various disease indications, and the total number of clinical trials involving the different types of stem cells.
- Current status of MSCs in clinical trials, the dominance of MSCs in the ongoing clinical trials involving stem cells, the various applications of MSCs in different disease indications, and the number of clinical trials involving MSCs for different disease types.
- The number of companies involved in the development of MSCs, the clinical trials sponsored by major companies, and their sustained search for MSCs-based cell therapy products.
- Key questions answered in this global strategic report are:
- How many companies are currently supporting the RM industry?
- What is the current regional breakdown of RM industry?
- How many RM products have been approved?
- What are the types of diseases are currently being pursued by RM companies?
- What are the major financial events, partnerships and acquisitions in RM sector?
- How do the large pharma companies perceive the value and long-term prospects of RM and CT?
- What are the major anticipated RM clinical events in 2015-16?
- What are the major therapeutic opportunities for the big pharma in RM and CT?
- How many CT product candidates have reached the Phase III stage and what are they?
- What are the CT product candidates being developed for cardiovascular diseases, central nervous system, wounds, spine and orthopedics, diabetes and autoimmune diseases?
- What are the major commercially available cell therapy products?
- What is the total number of cell therapy clinical trials at the global level?
- What are the major indications addressed by cell therapy clinical trials?
- What are the major cell therapy clinical trials that have reached Phase III?
- How many cell therapy clinical trials failed in the past year and what are they?
- What are the contributions of MSCs to the cell therapy industry?
- What are the biological properties of MSCs?
- What do MSCs get differentiated into?
- What bioactive molecules do the MSCs secrete?
- What are the immunomodulatory functions of MSCs?
- What are the factors impacting the acquisition of MSCs?
- What are the various sources of MSCs?
- What are the ongoing clinical trials using bone marrow-derived MSCs (BMMSCs) for kidney diseases?
- What are the major clinical trials focusing on diabetes using BMMSCs?
- What are the major clinical trials involving BMMSCs for cardiovascular diseases?
- What are the major clinical trials focusing on liver diseases by BMMSCs?
- What are the brain-related diseases addressed by clinical trials using BMMSCs?
- How many clinical trials are conducted for intestinal diseases using MSCs?
Follow
us on LinkedIn:
https://www.linkedin.com/company/marketresearchreports-biz
About
us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr.
Nachiket
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
No comments:
Post a Comment